相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
J. Sonnemann et al.
BRITISH JOURNAL OF CANCER (2014)
The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells
Shuo Chen et al.
PLOS ONE (2013)
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells
Eun-Taex Oh et al.
INVESTIGATIONAL NEW DRUGS (2012)
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
Jung Jin Hwang et al.
INVESTIGATIONAL NEW DRUGS (2012)
Mechanistic insights into aging, cell-cycle progression, and stress response
S. D. L. Postnikoff et al.
FRONTIERS IN PHYSIOLOGY (2012)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
Novel Structural Insights into Class I and II Histone Deacetylases
Ralf Ficner
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Use of DNA methylation for cancer detection: Promises and challenges
Jingde Zhu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Epigenetic diagnostics of cancer - the application of DNA methylation markers
Jaroslaw Paluszczak et al.
JOURNAL OF APPLIED GENETICS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone deacetylase inhibitors: discovery and development as anticancer agents
PA Marks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action
CL Zhang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Histone deacetylase inhibitors in programmed cell death and cancer therapy
PA Marks et al.
CELL CYCLE (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Histone deacetylase inhibitors and cancer: from cell biology to the clinic
H Hess-Stumpp
EUROPEAN JOURNAL OF CELL BIOLOGY (2005)
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation
M Welcker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7
M Yada et al.
EMBO JOURNAL (2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Histone deacetylase as a new target for cancer chemotherapy
M Yoshida et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
分享论文
